Strategies for primary and secondary stroke prevention in atrial fibrillation

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting 1-1.5% of Western adults.
• AF is a major stroke risk factor, increasing risk fivefold compared to the general population.
• Stroke prevention in AF patients is crucial, reducing stroke prevalence by approximately 25%.

Purpose of the Study:

• To review current strategies for stroke prevention in atrial fibrillation (AF) patients.
• To evaluate the efficacy and safety of available pharmacological and non-pharmacological interventions.
• To identify the optimal stroke prevention method for high-risk AF patients.

Main Methods:

• Review of existing literature on AF and stroke prevention.
• Analysis of clinical trial data for antiplatelet agents and oral anticoagulants.
• Assessment of novel anticoagulants and mechanical devices for stroke risk reduction.

Main Results:

• Antiplatelet agents are indicated for CHAD scores 0-1, reducing stroke risk by 20-25%.
• Oral anticoagulation with vitamin K antagonists is indicated for CHAD scores >1, reducing stroke risk by 62%.
• Novel anticoagulants and mechanical devices have shown limitations in efficacy or safety for AF stroke prevention.

Conclusions:

• Vitamin K antagonists are the current standard of care for stroke prevention in high-risk AF patients.
• No alternative to vitamin K antagonists has demonstrated comparable efficacy and safety for primary or secondary stroke prevention in this population.
• Further research into novel anticoagulants and devices is needed, but current evidence supports established therapies.